SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Niméus Emma) "

Sökning: WFRF:(Niméus Emma)

  • Resultat 21-30 av 41
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Niméus, Emma (författare)
  • Prognostic and treatment predictive factors for radio- and chemotherapy resistance in breast cancer patients- a step towards personlized medicine
  • 2009
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Breast cancer is the most common cancer form among women in the Western world. Although treatment has improved during the last decades, there is still a significant proportion of the patients who are not cured. To further improve clinical outcome we need new treatment strategies, new prognostic markers, and new treatment predictive factors for personalized medicine.In this dissertation I have focused on local relapse and distant recurrences, where the former is a tumor recurring in the same breast and the latter is distant spread in the body. I have focused on high through-put techniques, but have also evaluated one single factor, using immunohistochemistry. The most promising result is the gene expression profile for “radioresistance” found in a patient cohort consisting of 100 lymph node negative patients operated with breast conservation surgery and either postoperative radiotherapy or not. The samples were analyzed with oligonucleotide array. A gene expression profile was found that clearly separated patients who developed local recurrences despite radiotherapy (“radioresistance”) from patients without local recurrences (either with or without radiotherapy). The clinical consequence, if these results can be confirmed, would be that patients with a“radioresistant” gene profile should be offered mastectomy instead of breast conservation surgery and radiotherapy. In another patient cohort consisting of 85 node positive breast cancer patients treated with CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) we found a gene expression profile, using cDNA microarray, capable of distinguishing patients who developed distant recurrences from non-recurring patients. This profile was compared to a previously published gene list and to drug-associated genes from the literature. Our results were slightly better. However, our gene profile was not able to exceed the performance of conventional clinical markers. From the same patient cohort, we developed a protocol for protein extraction from the same samples used for RNA. We analyzed the protein expression pattern using 2-DE (two-dimensional electrophoresis) and found several differentially expressed proteins, both when comparing distant recurrences to no recurrences and estrogen receptor positive to estrogen receptor negative tumors. Similarities of regulated genes and proteins were also found when comparing the two studies. Finally, we investigated the prognostic importance of a proliferation marker, cyclin B1,in a case-control study. There were 190 lymph node negative breast cancer patients with no chemotherapy who died from breast cancer and 190 corresponding controls who were alive at the corresponding case’s time of death. Cyclin B1 was an independent prognostic proliferation marker and had a high reproducibility. The marker may be useful instead of histological grade, or as a complement, to identify patients in need of adjuvant chemotherapy. In conclusion, breast cancer is a heterogeneous disease and should be subdivided even more than it is today into different risk groups with the aid of new markers. We used different high through-put techniques to analyze hundreds to thousands of gene expressions and proteins. Our aim was to find new prognostic and predictive gene expressions and protein profiles that may improve individual treatment schemes and help provide personalized medicine. However, so far it is too early to conclude that the use of single markers can be eliminated, because we also found significant prognostic value of the proliferation marker cyclin B1.
  •  
22.
  • Niméus, Emma, et al. (författare)
  • Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
  • 2007
  • Ingår i: Journal of Pharmaceutical and Biomedical Analysis. - : Elsevier BV. - 0731-7085. ; 43:3, s. 1086-1093
  • Tidskriftsartikel (refereegranskat)abstract
    • Breast cancer is a heterogenous disease and it is of importance to select patients with regard to different prognosis and treatment sensitivity to individualize treatment regimes. In this study we successfully adapted a protein extraction protocol from mRNA extracted tumor samples enabling two-dimensional gel electrophoresis (2-DE) analysis of samples previously analyzed by cDNA microarray. The aim was to find candidate proteins that distinguish breast cancer patients with or without recurrences after adjuvant CMF (cyclophosphamide, methotrexate and 5-FU) treatment within four years to follow-up. We identified several proteins distinguishing the recurrence group from the non-recurrence group, especially in the ER and PgR positive subgroup (n = 7). The induced proteins were involved in translation/folding, iron ion binding, and protease inhibition, whereas proteins involved in signaling, ubiquitination, and splicing were decreased in expression. These results show that it is possible to use 2-DE to separate high abundant proteins in breast cancer tissue and to find discriminating proteins to identify patients with different prognosis after adjuvant CMF treatment.
  •  
23.
  • Sajic, Tatjana, et al. (författare)
  • Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
  • 2018
  • Ingår i: Cell Reports. - : Elsevier BV. - 2211-1247. ; 23:9, s. 5-2831
  • Tidskriftsartikel (refereegranskat)abstract
    • Cancer is mostly incurable when diagnosed at a metastatic stage, making its early detection via blood proteins of immense clinical interest. Proteomic changes in tumor tissue may lead to changes detectable in the protein composition of circulating blood plasma. Using a proteomic workflow combining N-glycosite enrichment and SWATH mass spectrometry, we generate a data resource of 284 blood samples derived from patients with different types of localized-stage carcinomas and from matched controls. We observe whether the changes in the patient's plasma are specific to a particular carcinoma or represent a generic signature of proteins modified uniformly in a common, systemic response to many cancers. A quantitative comparison of the resulting N-glycosite profiles discovers that proteins related to blood platelets are common to several cancers (e.g., THBS1), whereas others are highly cancer-type specific. Available proteomics data, including a SWATH library to study N-glycoproteins, will facilitate follow-up biomarker research into early cancer detection. Sajic et al. perform a multi-tumor plasma proteomic study in which they enrich and analyze tissue-secreted plasma glycoproteins to examine blood protein changes in early-stage localized cancers. They demonstrate that many proteins secreted upon platelet activation are changed in several tissue carcinomas, whereas others have changes specific to a single carcinoma type.
  •  
24.
  • Sigurjonsdottir, Gudbjörg, et al. (författare)
  • Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
  • 2023
  • Ingår i: Breast Cancer Research. - 1465-5411 .- 1465-542X. ; 25:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and further studies are needed to optimize clinical utility. Methods: We compared the concordance, prognostic value and gene expression between PD-L1 IHC expression by SP142 immune cell (IC) score and 22C3 combined positive score (CPS; companion IHC diagnostic assays for atezolizumab and pembrolizumab, respectively) in a population-based cohort of 232 early-stage TNBC patients. Results: The expression rates of PD-L1 for SP142 IC ≥ 1%, 22C3 CPS ≥ 10, 22C3 CPS ≥ 1 and 22C3 IC ≥ 1% were 50.9%, 27.2%, 53.9% and 41.8%, respectively. The analytical concordance (kappa values) between SP142 IC+ and these three different 22C3 scorings were 73.7% (0.48, weak agreement), 81.5% (0.63) and 86.6% (0.73), respectively. The SP142 assay was better at identifying 22C3 positive tumors than the 22C3 assay was at detecting SP142 positive tumors. PD-L1 (CD274) gene expression (mRNA) showed a strong positive association with all two-categorical IHC scorings of the PD-L1 expression, irrespective of antibody and cut-off (Spearman Rho ranged from 0.59 to 0.62; all p-values < 0.001). PD-L1 IHC positivity and abundance of tumor infiltrating lymphocytes were of positive prognostic value in univariable regression analyses in patients treated with (neo)adjuvant chemotherapy, where it was strongest for 22C3 CPS ≥ 10 and distant relapse-free interval (HR = 0.18, p = 0.019). However, PD-L1 status was not independently prognostic when adjusting for abundance of tumor infiltrating lymphocytes in multivariable analyses. Conclusion: Our findings support that the SP142 and 22C3 IHC assays, with their respective clinically applied scoring algorithms, are not analytically equivalent where they identify partially non-overlapping subpopulations of TNBC patients and cannot be substituted with one another regarding PD-L1 detection. Trial registration The Swedish Cancerome Analysis Network - Breast (SCAN-B) study, retrospectively registered 2nd Dec 2014 at ClinicalTrials.gov; ID NCT02306096.
  •  
25.
  • Sjöström, Martin, et al. (författare)
  • A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery
  • 2015
  • Ingår i: Journal of Proteome Research. - : American Chemical Society (ACS). - 1535-3893 .- 1535-3907. ; 14:7, s. 2807-2818
  • Tidskriftsartikel (refereegranskat)abstract
    • It is of highest importance to find proteins responsible for breast cancer dissemination, for use as biomarkers or treatment targets. We established and performed a combined nontargeted LC MS/MS and a targeted LC SRM workflow for discovery and validation of protein biomarkers. Eighty breast tumors, stratified for estrogen receptor status and development of distant recurrence (DR +/-), were collected. After enrichment of N-glycosylated peptides, label-free LC-MS/MS was performed on each individual tumor in triplicate. In total, 1515 glycopeptides from 778 proteins were identified and used to create a map of the breast cancer N-glycosylated proteome. Based on this specific proteome map, we constructed a 92-plex targeted label-free LC-SRM panel. These proteins were quantified across samples by LC SRM, resulting in 10 proteins consistently differentially regulated between DR+/DR- tumors. Five proteins were further validated in a separate cohort as prognostic biomarkers at the gene expression level. We also compared the LC-SRM results to clinically reported HER2 status, demonstrating its 'clinical accuracy. In conclusion, we demonstrate a combined mass spectrometry strategy, at large scale on clinical samples, leading to the identification and validation of five proteins as potential biomarkers for breast cancer recurrence. All MS data are available via ProteomeXchange and PASSEL with identifiers PXD001685 and PASS00643.
  •  
26.
  • Sjöström, Martin, et al. (författare)
  • Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery : a long-term follow-up of the SweBCG91-RT randomised trial
  • 2020
  • Ingår i: Molecular Oncology. - : Wiley. - 1574-7891 .- 1878-0261. ; 14:11, s. 2713-2726
  • Tidskriftsartikel (refereegranskat)abstract
    • Experimental studies suggest that hepatocyte growth factor (HGF) and its transmembrane tyrosine kinase receptor, Met, in part also relying on Akt kinase activity, mediate radioresistance. We investigated the importance of these biomarkers for the risk of ipsilateral breast tumour recurrence (IBTR) after adjuvant radiotherapy (RT) in primary breast cancer. HGF, phosphorylated Met (pMet) and phosphorylated Akt (pAkt) were evaluated immunohistochemically on tissue microarrays from 1004 patients in the SweBCG91-RT trial, which randomly assigned patients to breast-conserving therapy, with or without adjuvant RT. HGF was evaluated in the stroma (HGFstr); pMet in the membrane (pMetmem); HGF, pMet and pAkt in the cytoplasm (HGFcyt, pMetcyt, pAktcyt); and pAkt in the nucleus (pAktnuc). The prognostic and treatment predictive effects were evaluated to primary endpoint IBTR as first event during the first 5 years. Patients with tumours expressing low levels of HGFcyt and pMetcyt and high levels of pAktnuc derived a larger benefit from RT [hazard ratio (HR): 0.11 (0.037–0.30), 0.066 (0.016–0.28) and 0.094 (0.028–0.31), respectively] compared to patients with high expression of HGFcyt and pMetcyt, and low pAktnuc [HR: 0.36 (0.19–0.67), 0.35 (0.20–0.64) and 0.47 (0.32–0.71), respectively; interaction analyses: P = 0.052, 0.035 and 0.013, respectively]. These differences remained in multivariable analysis when adjusting for patient age, tumour size, histological grade, St Gallen subtype and systemic treatment (interaction analysis, P-values: 0.085, 0.027, and 0.023, respectively). This study suggests that patients with immunohistochemically low HGFcyt, low pMetcyt and high pAktnuc may derive an increased benefit from RT after breast-conserving surgery concerning the risk of developing IBTR.
  •  
27.
  • Sjöström, Martin, et al. (författare)
  • Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
  • 2018
  • Ingår i: Breast Cancer Research. - : Springer Science and Business Media LLC. - 1465-5411 .- 1465-542X. ; 20:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Adjuvant radiotherapy is the standard of care after breast-conserving surgery for primary breast cancer, despite a majority of patients being over- or under-treated. In contrast to adjuvant endocrine therapy and chemotherapy, no diagnostic tests are in clinical use that can stratify patients for adjuvant radiotherapy. This study presents the development and validation of a targeted gene expression assay to predict the risk of ipsilateral breast tumor recurrence and response to adjuvant radiotherapy after breast-conserving surgery in primary breast cancer. Methods: Fresh-frozen primary tumors from 336 patients radically (clear margins) operated on with breast-conserving surgery with or without radiotherapy were collected. Patients were split into a discovery cohort (N = 172) and a validation cohort (N = 164). Genes predicting ipsilateral breast tumor recurrence in an Illumina HT12 v4 whole transcriptome analysis were combined with genes identified in the literature (248 genes in total) to develop a targeted radiosensitivity assay on the Nanostring nCounter platform. Single-sample predictors for ipsilateral breast tumor recurrence based on a k-top scoring pairs algorithm were trained, stratified for estrogen receptor (ER) status and radiotherapy. Two previously published profiles, the radiosensitivity signature of Speers et al., and the 10-gene signature of Eschrich et al., were also included in the targeted panel. Results: Derived single-sample predictors were prognostic for ipsilateral breast tumor recurrence in radiotherapy-treated ER+ patients (AUC 0.67, p = 0.01), ER+ patients without radiotherapy (AUC = 0.89, p = 0.02), and radiotherapy-treated ER- patients (AUC = 0.78, p < 0.001). Among ER+ patients, radiotherapy had an excellent effect on tumors classified as radiosensitive (p < 0.001), while radiotherapy had no effect on tumors classified as radioresistant (p = 0.36) and there was a high risk of ipsilateral breast tumor recurrence (55% at 10 years). Our single-sample predictors developed in ER+ tumors and the radiosensitivity signature correlated with proliferation, while single-sample predictors developed in ER- tumors correlated with immune response. The 10-gene signature negatively correlated with both proliferation and immune response. Conclusions: Our targeted single-sample predictors were prognostic for ipsilateral breast tumor recurrence and have the potential to stratify patients for adjuvant radiotherapy. The correlation of models with biology may explain the different performance in subgroups of breast cancer.
  •  
28.
  • Sjöström, Martin, et al. (författare)
  • Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial.
  • 2017
  • Ingår i: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 1527-7755. ; 35:28, s. 3222-3229
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose To evaluate the effect of adjuvant radiotherapy (RT) after breast conservation surgery in different breast cancer subtypes in a large, randomized clinical trial with long-term follow-up. Patients and Methods Tumor tissue was collected from 1,003 patients with node-negative, stage I and II breast cancer who were randomly assigned in the Swedish Breast Cancer Group 91 Radiotherapy trial between 1991 and 1997 to breast conservation surgery with or without RT. Systemic adjuvant treatment was sparsely used (8%). Subtyping was performed with immunohistochemistry and in situ hybridization on tissue microarrays for 958 tumors. Results RT reduced the cumulative incidence of ipsilateral breast tumor recurrence (IBTR) as a first event within 10 years for luminal A-like tumors (19% v 9%; P = .001), luminal B-like tumors (24% v 8%; P < .001), and triple-negative tumors (21% v 6%; P = .08), but not for human epidermal growth factor receptor 2-positive (luminal and nonluminal) tumors (15% v 19%; P = .6); however, evidence of an overall difference in RT effect between subtypes was weak ( P = .21). RT reduced the rate of death from breast cancer (BCD) for triple-negative tumors (hazard ratio, 0.35; P = .06), but not for other subtypes. Death from any cause was not improved by RT in any subtype. A hypothesized clinical low-risk group did not have a low risk of IBTR without RT, and RT reduced the rate of IBTR as a first event after 10 years (20% v 6%; P = .008), but had no effect on BCD or death from any cause. Conclusion Subtype was not predictive of response to RT, although, in our study, human epidermal growth factor receptor 2-positive tumors seemed to be most radioresistant, whereas triple-negative tumors had the largest effect on BCD. The effect of RT in the presumed low-risk luminal A-like tumors was excellent.
  •  
29.
  •  
30.
  • Stenemo, Markus, et al. (författare)
  • Cancer associated proteins in blood plasma : Determining normal variation
  • 2016
  • Ingår i: Proteomics. - : Wiley. - 1615-9853. ; 16:13, s. 1928-1937
  • Tidskriftsartikel (refereegranskat)abstract
    • Protein biomarkers have the potential to improve diagnosis, stratification of patients into treatment cohorts, follow disease progression and treatment response. One distinct group of potential biomarkers comprises proteins which have been linked to cancer, known as cancer associated proteins (CAPs). We determined the normal variation of 86 CAPs in 72 individual plasma samples collected from ten individuals using SRM mass spectrometry. Samples were collected weekly during 5 weeks from ten volunteers and over one day at nine fixed time points from three volunteers. We determined the degree of the normal variation depending on interpersonal variation, variation due to time of day, and variation over weeks and observed that the variation dependent on the time of day appeared to be the most important. Subdivision of the proteins resulted in two predominant protein groups containing 21 proteins with relatively high variation in all three factors (day, week and individual), and 22 proteins with relatively low variation in all factors. We present a strategy for prioritizing biomarker candidates for future studies based on stratification over their normal variation and have made all data publicly available. Our findings can be used to improve selection of biomarker candidates in future studies and to determine which proteins are most suitable depending on study design.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 41
Typ av publikation
tidskriftsartikel (37)
konferensbidrag (2)
doktorsavhandling (2)
Typ av innehåll
refereegranskat (38)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Nimeus, Emma (40)
Fernö, Mårten (12)
Killander, Fredrika (8)
Malmström, Per (7)
Karlsson, Per, 1963 (7)
Holmberg, Erik, 1951 (6)
visa fler...
Rydén, Lisa (5)
Staaf, Johan (5)
Malmström, Johan (5)
Bendahl, Pär Ola (4)
Ehinger, Anna (4)
Hartman, Johan (4)
Aebersold, Ruedi (4)
Lundstedt, Dan, 1970 (4)
Borg, Åke (4)
Grabau, Dorthe (4)
Wärnberg, Fredrik (3)
Fredriksson, Irma (3)
Altucci, Lucia (3)
Mai, Antonello (3)
Brueffer, Christian (3)
Pyl, Paul Theodor (3)
Pekar, Gyula (3)
Benedetti, Rosaria (3)
Zackrisson, Sophia (2)
Stål, Olle (2)
Edén, Patrik (2)
Kovács, Anikó (2)
Marko-Varga, György (2)
Aine, Mattias (2)
Häkkinen, Jari (2)
Mitra, Shamik (2)
Vallon-Christersson, ... (2)
Folkesson, Elin (2)
Tang, Man-Hung Eric (2)
Dahlgren, Malin (2)
Chen, Yilun (2)
Olsson, Eleonor (2)
Winter, Christof (2)
Saal, Lao (2)
Gruvberger, Sofia (2)
Krogh, Morten (2)
Bosch, Ana (2)
Peterson, Carsten (2)
Johnsson, Anders (2)
Malander, Susanne (2)
Kovács, Anikó, 1961 (2)
Malmström, Lars (2)
Hartman, Linda (2)
Rinner, Oliver (2)
visa färre...
Lärosäte
Lunds universitet (39)
Göteborgs universitet (9)
Karolinska Institutet (9)
Uppsala universitet (3)
Linköpings universitet (2)
Umeå universitet (1)
visa fler...
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (41)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (41)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy